B O O K - American College of Rheumatology

Session Overview:
The advent of biological therapies has dramatically improved the
treatment of rheumatoid arthritis, providing proof of principle
that targeted interventions may be effective. Still, not all
patients respond and there is a need to develop new therapies.
This symposium will address the role of toll-like receptors in the
pathogenesis of rheumatoid arthritis as well as their potential
as a new therapeutic target for the treatment of inflammatory
disease.
Upon completion of this session, participants should be able to:
• appraise the role of toll-like receptors in two key effector
cells involved in the pathogenesis of rheumatoid arthritis -
macrophages and fibroblast-like synoviocytes
• identify the toll-like receptors as a new therapeutic target in a
variety of immune-mediated inflammatory disorders
ACR Clinical Symposia
2:30 - 4:00 pm
Thomas J. Murphy Ballroom
Mouse to House: Lessons Learned About Lupus
Therapeutics P PS
Moderator: Richard A. Furie, MD; North Shore Long Island
Jewish Health System; Lake Success, NY
2:30 pm
Protective and Pathogenic Functions for B Cells During Systemic
Autoimmunity in Mice
Thomas Tedder, PhD; Duke University Medical Center; Durham,
NC
2:55 pm
Do Biologic Responses to Therapeutic Interventions in Mice
Predict Results in Human Lupus?
Anne Davidson, MB, BS; Feinstein Institute for Medical Research;
Manhasset, NY
Hall A3
The Great Debate: Is it Time to Use Biologics as Firstline
Therapy in Rheumatoid Arthritis? cP PS ARS
Moderator: Eric M. Ruderman, MD; Northwestern University
School; Chicago, IL
2:30 pm
Resolved: Aggressive Use of Non-biologic DMARDs is as
Effective as Biologics in the Management of Rheumatoid
Arthritis (Con)
Daniel E. Furst, MD; University of California-Los Angeles School
of Medicine; Los Angeles, CA
3:15 pm
Resolved: Aggressive Use of Non-biologic DMARDs is as
Effective as Biologics in the Management of Rheumatoid
Arthritis (Pro)
Marc D. Cohen, MD; National Jewish Medical and Research
Center; Denver, CO
Session Overview:
Biologic therapy has unquestionably altered the landscape of
treatment for rheumatoid arthritis, and some have even begun
to suggest that it is time for these agents to supplant nonbiologic
therapy as first-line therapy. Addressing this question
involves complicated and intertwining issues of efficacy,
toxicity and cost. The presenters of this session will debate
whether biologic therapy should be the initial therapy for the
management of rheumatoid arthritis.
Upon completion of this session, participants should be able to:
• describe the data supporting first-line use of biologic therapy
in rheumatoid arthritis
• identify the limitations of biologic therapies that make their
use as first-line therapy inadvisable
• identify gaps in data that will need to be filled in order to
resolve question of biologic use as first-line therapy
monday
3:30 pm
Lessons Learned from Clinical Trials in Human Systemic Lupus
Erythematosus
Bevra H. Hahn, MD; University of California-Los Angeles School
of Medicine; Los Angeles, CA
Session Overview:
Significant advances in our knowledge of immune system
disturbances in lupus have been made over the last several
decades. However, understanding the science has not yet
translated into a new drug for this potentially devastating illness.
Addressing mouse models and human studies, this symposium
will relate pathogenetic concepts to strategies for therapeutic
interventions.
Upon completion of this session, participants should be able to:
• discuss animal models of lupus and how they have advanced
the development of therapeutics for human disease
• describe humoral and cellular effects of therapeutic
interventions in patients with lupus
• summarize clinical trial data and reconcile the variability of
observed responses
ACR Concurrent Abstract Sessions
2:30 - 4:00 pm
A402
Biology and Pathology of Bone and Joint: Molecular
Basis of Osteoarthritis
Moderators: Tariq M. Haqqi, MPH, PhD; Metro Health Medical
Center; Richmond Heights, OH
Hiroshi Asahara, MD, PhD; The Scripps Research Institute; La
Jolla, CA
2:30 pm
629. TNF and IL-6 Differentially Regulate the Production of
DKK-1, a Master Regulator of Bone Remodelling, by Fibroblast-
Like Synoviocytes.
Nataliya Yeremenko 2 , Karin Polzer 3 , Gemma Righter 2 , Radjesh
Bisoendial 2 , Jochen Zwerina 3 , Georg Schett 3 , Paul P. Tak 1 and
Dominique Baeten 1 , 1 Academic Med Ctr/Univ of Amsterdam,
Amsterdam, The Netherlands, 2 Division of Clinical Immunology
and Rheumatology, Academic Medical Centre/University of
Amsterdam, Amsterdam, The Netherlands, 3 Internal Medicine 3 ,
Erlangen, Germany
2010 Program Book 39